Why the pros say there's still a lot of upside to Johnson & Johnson after earnings beat

Analysts and investors took to CNBC to discuss the latest action for Johnson & Johnson shares.

Market Movers rounded up the best reactions from investors and analysts on Johnson & Johnson 's latest quarterly results. The experts, including Jim Cramer , discussed the health-care giant as its shares fell 2.8% on Tuesday.

Johnson & Johnson posted first-quarter adjusted earnings and revenue that beat expectations , but dialed back its sales guidance for its pharmaceutical business. Johnson & Johnson is currently held in Jim Cramer's Charitable Trust portfolio.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Alphabet shares dip to start the week. Here's what the experts have to sayAnalysts and investors took to CNBC to discuss the latest action for Alphabet shares.
Read more »

Johnson & Johnson beats Q1 consensus estimates and raises guidanceJohnson & Johnson’s stock rose 1.4% in premarket trade Tuesday, after the consumer health and pharma company beat consensus estimates for its first quarter...
Read more »

JNJ Stock Price | Johnson & Johnson Stock - Investing.comGet today's JNJ stock price and latest Johnson & Johnson stock news as well as JNJ real-time stock quotes, technical analysis, full financials and more.
Read more »

Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 OutlookFirst-quarter earnings were wiped out by a $6.9 billion charge tied to litigation and other costs from its Covid-19 vaccine commitments.
Read more »

Stocks making the biggest moves premarket: Johnson & Johnson, Goldman Sachs, Sunrun and moreShares of Goldman Sachs shed nearly 4% after missing revenue estimates in its first-quarter earnings released before Tuesday's opening bell.
Read more »

Johnson & Johnson beats on earnings and revenue, raises full-year guidanceEARNINGS: J&J reported adjusted earnings and revenue that topped Wall Street’s expectations, and lifted its full-year forecast. CFO Joseph Wolk joins us to discuss.
Read more »